StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3086% above fair value
$286.00−2.84 (-0.98%)

Close on Nov 3, 2026Market cap $505.40BP/E 80.8Yield 2.33%

AbbVie Adjusted R&D Expense % of Net Revenues by Quarter

Adjusted R&D Expense % of Net Revenues — Non-GAAP (%) (%)

AbbVie Adjusted R&D Expense % of Net Revenues: 13.6% in Q2 2026, down 0.1 pts from a year earlier.

Latest, Q2 2026
13.6%
Period ended Jun 30, 2026
Change on a year earlier
-0.1 pts
13.7% in Q2 2025
History
11 quarters
Since Q3 2022
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“On a GAAP basis, research and development (R&D) expense was 13.8 percent of net revenues. The adjusted R&D expense was 13.6 percent of net revenues.”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Earnings Release.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdjusted R&D Expense % of Net Revenues — Non-GAAP (%) (%)Year on yearSource
Q2 2026Jun 30, 202613.6%-0.1 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202615.1%-0.3 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202515.4%+0.3 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202514.3%+0.1 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 202513.7%+0.4 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202515.4%+0.7 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202415.1%–Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 202414.2%–Form 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202413.3%–Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 202414.7%–Form 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q3 2022Sep 30, 202210.8%–Form 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Adjusted R&D Expense % of Net Revenues (%), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd-adj-pct-rev

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.

See a number that looks wrong?